Unknown

Dataset Information

0

Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade.

ABSTRACT:

SUBMITTER: Casadevall D 

PROVIDER: S-EPMC7450962 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade.

Casadevall David D   Li Xiaotong X   Powles Ryan L RL   Wali Vikram B VB   Buza Natalia N   Pelekanou Vasiliki V   Dhawan Arjun A   Foldi Julia J   Szekely Borbala B   Lopez-Giraldez Francesc F   Hatzis Christos C   Pusztai Lajos L  

JCO precision oncology 20190510

Similar Datasets

Unknown Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer.
| S-EPMC11297096 | biostudies-literature
Unknown Neoadjuvant PD-1/PD-L1 inhibitors plus chemotherapy in resectable gastric and gastroesophageal junction cancer.
| S-EPMC11535811 | biostudies-literature
Unknown PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Asian patients with advanced triple-negative breast cancer: a phase III RCTs based meta-analysis.
| S-EPMC11906427 | biostudies-literature
Unknown Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer.
| S-EPMC9817764 | biostudies-literature
Unknown PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer.
| S-EPMC10712197 | biostudies-literature
Unknown Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer.
| S-EPMC7539780 | biostudies-literature
Unknown Neoadjuvant anlotinib/sintilimab plus chemotherapy in triple-negative breast cancer (NeoSACT): Phase 2 trial.
| S-EPMC12281363 | biostudies-literature
Unknown Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy.
| S-EPMC9744414 | biostudies-literature
Unknown PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy.
| S-EPMC7916886 | biostudies-literature
Unknown A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma.
| S-EPMC9898180 | biostudies-literature